Skip to content

NIAID: further information on positive study of remdesivir in COVID-19


photo of book by Peter H courtesy of

A news release from NIAID (National Institute for Allergy and Infectious Diseases) dated April 29 provides more information on the positive results of a study of remdesivir in COVID-19.  Here is an excerpt:

Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (p=0.059).

Medpage today also reported on this trial and another one by Gilead comparing five and ten-day courses of remdesivir.  It appears that both courses of treatment were equally effective.  Finally, the same article reported that the Chinese trial mentioned last week was “inconclusive” because not enough patients were enrolled to obtain statistical significance.  Full results of that trial were published in the Lancet on April 29.  237 patients were enrolled, not enough to achieve statistical power to discern a difference (although patients on the drug recovered more quickly).  The full article in Lancet is behind a paywall, but from what I read earlier, patients were not given remdesivir early enough to get full benefit from the drug.

That’s it for me today.  Thanks for reading this far.

No comments yet

Leave a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: